Literature DB >> 12161035

Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis.

Kenichi Sakurai1, Jian-Ping Zou, Jolynne R Tschetter, Jerrold M Ward, Gene M Shearer.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated demyelinating disease of the central nervous system (CNS). Indoleamine 2,3-dioxygenase (IDO) is an enzyme that catabolizes tryptophan, which can result in the death of T lymphocytes. This effect of IDO is inhibited by 1-methyl-tryptophan (1-MT). We used a murine model of EAE to demonstrate: (1) opposing patterns of spinal cord IDO and interferon-gamma (INF-gamma) mRNA expression through the preclinical, acute and remission I phases of EAE; (2) a change in the kynurenine-to-tryptophan (K/T) ratio during these same phases; and (3) 1-MT-induced exacerbation of clinical and histologic disease parameters during EAE. These results suggest that IDO may contribute to the regulation of T cell activity associated with the different phases of this animal model of multiple sclerosis (MS).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161035     DOI: 10.1016/s0165-5728(02)00176-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  80 in total

1.  Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients.

Authors:  Amena W Smith; Bently P Doonan; William R Tyor; Nada Abou-Fayssal; Azizul Haque; Naren L Banik
Journal:  J Neuroimmunol       Date:  2010-11-13       Impact factor: 3.478

Review 2.  Failed central nervous system regeneration: a downside of immune privilege?

Authors:  Ingo Bechmann
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

3.  Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis.

Authors:  Raghava Potula; Larisa Poluektova; Bryan Knipe; Jesse Chrastil; David Heilman; Huanyu Dou; Osamu Takikawa; David H Munn; Howard E Gendelman; Yuri Persidsky
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

Review 4.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

5.  Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells.

Authors:  Oscar D Cano; Gabriele Neurauter; Dietmar Fuchs; Gene M Shearer; Adriano Boasso
Journal:  Neurosci Lett       Date:  2008-04-18       Impact factor: 3.046

Review 6.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Authors:  David H Munn; Madhav D Sharma; Deyan Hou; Babak Baban; Jeffrey R Lee; Scott J Antonia; Jane L Messina; Phillip Chandler; Pandelakis A Koni; Andrew L Mellor
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.

Authors:  Jie Wen; Prasanth S Ariyannur; Rachel Ribeiro; Mikiei Tanaka; John R Moffett; Batool F Kirmani; Aryan M A Namboodiri; Yumin Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-25       Impact factor: 4.147

9.  The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function.

Authors:  Jia Ni; Yi-Na Zhu; Xiang-Gen Zhong; Yu Ding; Li-Fei Hou; Xian-Kun Tong; Wei Tang; Shiro Ono; Yi-Fu Yang; Jian-Ping Zuo
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 10.  IDO: a double-edged sword for T(H)1/T(H)2 regulation.

Authors:  Hui Xu; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  Immunol Lett       Date:  2008-09-29       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.